Updated Weight Loss Strategies

New APP Updates in Treatment of Obesity and Bariatric Surgery James Healy, MD & Jessica Williams MD

> Use of GLP-1 Agents Fadi Al Khayer, MD

Diets Don't Work – A Lifestyle Medicine Approach Kathleen Mueller, MD



Bariatric Surgery in Adolescents – Approaches and Outcomes

> Division of Obesity & Weight Management Connecticut Children's

James Healy, MD, MHS, FACS










• I have no relevant financial disclosures or conflicts of interest to disclose.

Bariatric Surgery Options





Sleeve gastrectomy

- Smaller stomach restrictive
- Changes in gut hormones

Roux-en-Y gastric bypass

- Small pouch restrictive
- Malabsorptive
- Changes in gut hormones

Adjustable Gastric Band

- Restrictive only
- > 40% re-operation rate

AAP Policy Statement: December 2019



- Watchful waiting may lead to higher BMI and comorbidities
- Better outcomes if surgery before BMI 50
- Timely referrals to high-quality multidisciplinary center: American Society for Metabolic and Bariatric Surgery (ASMBS) has an accreditation program, and a specific adolescent designation

Hard of the solution of Adolescent Metabolis and Bandine outgory				
Wt Criteria	Comorbid Conditions			
Class 2 obesity, BMI ≥35, or 120% of the 95th percentile for age and sex, whichever is lower Class 3 obesity, BMI ≥40, or 140% of the 95th percentile for age and sex, whichever is lower	sleep apnea (AHI $>$ 5), T2DM, IIH, NASH, Blount disease, SCFE, GERD, and hypertension			

TABLE 1 Indications and Contraindications for Adolescent Metabolic and Bariatric Surgery



AHI, Apnea-Hypopnea Index; GERD, gastroesophageal reflux disease; IIH, idiopathic intracranial hypertension; NASH, nonalcoholic steatohepatitis; SCFE, slipped capital femoral epiphysis; T2DM, type 2 diabetes mellitus.

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices. Pediatrics. December 2019



We review all the possible risks with patients before surgery:

- An individualized risk assessment will always depend on individual comorbidities
- Infection 1:200
- Bleeding requiring transfusion or re-operation 1:200
- **Transient** nausea, reflux, difficulty swallowing 95%
- Injury to nearby organs (liver, spleen, intestine, diaphragm, pancreas): 1:3000
- Leak from staple line: rare
- DVT/PE: rare
- Death: exceptionally rare
- Eventual weight re-gain: approximately 10% over a 5-year period
- Request referral to plastic surgery for redundant skin: approximately 15%



What needs to be done prior to the operating room?

- All patients go through an extensive multidisciplinary evaluation and workup over at least a 6 month period.
- Specific preop requirements are aimed at reduction of risk:
 - o 6 months of nutritional education (reduces risk of weight regain)
 - o Physical therapy
 - Support group meeting(s)
 - $\circ\,$ Standard full lab panel including lipids, HbA1c, thyroid labs, LFTs $\,$
 - Sleep study and CPAP if indicated (reduces risk of cardiac and respiratory complications postop)
 - Upper GI swallow study (to evaluate for previously unknown malrotation or hiatal hernia)
 - o Right upper quadrant US (to evaluate for evidence of hepatic steatosis and presence of gallstones)
 - If workup suggestive of NAFLD or NASH, we can consider an MRI with elastography instead of UGI and RUQ US to estimate degree of fibrosis and evaluate liver size and stiffness to help reduce risk.


Who are our patients?




Baseline Demographics:

- Age: average 17 (range 12-24)
- Gender: 75% Female

 37.8% White or Caucasian
 28.3% Black or African American
 49.2% Hispanic
- Public insurance 65.6%
- BMI: average 47.6 (range: 35 71.6)
- HbA1c on enrollment: average 5.5 (min 4.6, max 11.9)
- Hepatic steatosis present in 50%






What is the recovery and operation like?

Operative Details

- 2-surgeon approach in 100% of cases currently (Drs. Finck and Healy)
- Median operative time: (78 min)
- Laparoscopic 88.1% Robotic 11.9%
- Selective liver biopsy 35%
- Cholecystectomy 10%
- Number of postop narcotics doses: median 2 doses
- Length of stay: median 2 nights
- Time to walking: patients walk the day of surgery
- Swimming/soaking: avoid for 10 days
- Heavy lifting/sports: avoid for 14 days








Compliance with aspects of the ERAS protocol


- Preop carbohydrate drink (evening before surgery and morning of surgery): 61%
- Scopolamine patch placed in preop: 100%
- Lovenox preop: 100%
- $\circ\,$ Preop meds:
 - -Zofran 100%
 - -Gabapentin 98.9%
 - -Celebrex 98.9%
 - -Acetaminophen 100%
 - Famotidine 100%
- TAP block intraop 100%
- $\circ~$ Intraop meds:
 - -Zofran 4mg 100%
 - -decadron 10mg 100%
 - Haldol 0.5mg 98.9%

Postop meds: decadron 10mg 8 hrs postop x1 95.5%



Selective biopsy results

- Liver biopsy indicated in 35% of patients
- >50% of patients undergoing biopsy already have evidence of hepatic fibrosis
- 6.3% identified with stage IV fibrosis
- Need to identify patients at risk for later advanced liver disease and refer to hepatology for counseling and treatment






Counts/frequency: F0 (15, 46.9%), F1 (9, 28.1%), F2 (6, 18.8%), F3 (0, 0.0%), F4 (2, 6.3%)

Hepatic Fibrosis

Weight Loss Outcomes






Weight lost from maximum preop weight by days following bariatric surgery

Outcomes in Teens: Teen LAB data





Surgical Outcomes - Comorbidities


Sleeve Gastrectomy and RYGB

Comorbidity resolution:

- \circ Diabetes: 86% (53% adult) at 5 yrs
 - Teens: 88% used meds before surgery, none after
 - Adults: 79% meds before surgery, 26% after
- o HTN: 68% (41% adult) at 5 yrs
 - Teens: 57% used meds before surgery, 11% after
 - Adults: 68% before surgery, 33% after

• Dyslipidemia: 66%

 $\circ\,\text{Fatty}\,\text{liver}$





Wrap Up/Questions

Contact



jhealy@connecticutchildrens.org – James Healy cfinck@connecticutchildrens.org - Christine Finck

Obesity Center at Connecticut Children's: 860-837-6717 <u>obesity@connecticutchildrens.org</u> <u>www.connecticutchildrens.org/obesity</u>





Obesity Treatment in Children and Adolescents – What's New?

Division of Obesity & Weight Management Connecticut Children's

Jessica Williams, MD, F-AAP, D-ABOM









- Discuss updated American Academy of Pediatrics clinical practice guidelines for evaluation and treatment of pediatric obesity treatment:

 how they have or have not affected a tertiary care pediatric obesity practice
 success rates
- Partnering on referrals between primary care providers and our team

New Guidelines



- Emphasis on CHRONIC nature or obesity
- Emphasis on multimodal causes of obesity and multimodal solutions
- No more "watchful waiting"
- Streamlined/clarified evaluation of obesity co-morbidities
- When to refer...

Risk Factors



xample Description		 Monogenetic syndromes and polygenetic effects
A. Policy factors	Marketing of unhealthy foods	 b. Epigenetic effects
A Folicy lactors	Underresourced communities	D.2. Prenatal risk
	Food insecurity	a. Parental obesity
B. Neighborhood and community factors	1. School environment	b. Maternal weight gain
a. Reighborhood and commany racers	2 Lack of fresh food access	c. Gestational diabetes
	3. Fast food proximity	d. Maternal smoking
	4. Access to safe physical activity	D.3. Postnatal risk
	5. Environmental health	a. Birth weight
C. Family and home environment factors	1. Parenting feeding style	b. Early breastfeeding cessation and
	2. Sugar-sweetened beverages	formula feeding
	3. Portion sizes	c. Rapid weight gain during infancy and
	 Snacking behavior 	early childhood
	5. Dining out and family meals	d. Early use of antibiotics
	6. Screen time	D.4. Childhood risk
	Sedentary behavior	a. Endocrine disorders
	 8. Sleep duration 9. Environmental smoke exposure 	b. Children and youth with special health care needs
	10. Psychosocial stress	1. Children with autism spectrum disorder
	 Adverse childhood experiences 	2. Children with developmental and
		physical disabilities
		3. Children with myelomeningocele
		c. Attention-deficit/hyperactivity disorder
40% to 70% genetic		d. Weight-promoting appetitive traits
contribution to an individual's		e. Medication use (weight-promoting
		medications)
obocity rick		f. Depression

obesity risk

Overweight and Obesity in Early Childhood Tracks Into Later Life: No More Watchful Waiting



Rapid increases in weight for length in the first 6 months increases risk of overweight at 3 years¹ Children with BMI>85% at ages 2-5 years are 5 times more likely to be overweight at age 12² Severely obese (BMI>98%ile) 2year-olds have an 80% chance of being obese by age 35, and 5year-olds have a 90% chance³

Simulated growth trajectories predict 57% of todays children will be obese at age 35³ Among adolescents with obesity, the most rapid weight gain occurred between 2-6 years of age⁴


1 Taveras, et al. *Pediatrics*. (2009);123(4):1177-1183 2 Nader, et al. . *Pediatrics*. (2006); 118(3)e594-e601 3 Ward, et al. *NEJM*. (2017); 377*:*2145-53 Ward, et al. *NEJM*. (2017); 377*:*2145-53 4 Geserick, et al. NEJM. (2018); 379(14): 1303-1312

Severity of Pediatric Obesity



For pediatric patients with severe obesity

• Severe obesity is > 120% of the 95th percentile (Class 2 or greater)



Evaluation for Comorbidities




- Lipids fasting specimen
 2-9yo obesity; 10yo and up for overweight or obesity
- Glucose testing fasting glucose, A1c or 2h glucose (NOT insulin!). OGTT is usually a conformational test not first line
 - Test with symptoms, risk factors (incl AN!), screen all obesity 10y and greater
 - $\circ~$ Type II DM has faster progression in children than adults
- Fatty liver screening ALT (not a CMP), 10yo and up, and younger with more severe obesity

 Up to 34% of children with obesity have NAFLD
- HTN BP screening in the office every visit 3yrs old and up for overweight or obesity
- **OSA** refer to sleep study for 1 or more symptoms
- PCOS look for menstrual irregularities and signs of hyperandrogenism
- **Depression** monitor with self reported tools 12 and up
- Ortho SCFE and Blount
- **Pseudotumor** high index of suspicion for new/progressive ha, especially in female patients

Treatment of Obesity



- Look at the whole picture environmental, familial, social, educational, social determinants of health
- Chronic treatment emphasized continuous coordinated care
- Emphasis on Motivational Interviewing
- Foundational: Intensive Health Behavior and Lifestyle Treatment 26h over 3-12mo to achieve BMI reduction or attenuation of weight gain



Intensive Health Behavior and Lifestyle Treatment (IHBLT)

* PCPs and/or PHCPs with training in obesity as well as other professionals trained in behavior and lifestyle fields such as dietitians, exercise specialists and behavioral health practitioners

Intensive Behavioral and Lifestyle Treatment



- Family based, 26hrs over 3-12 mo
- Can be in an academic center
- PCP home with partnerships: YMCA, parks and rec, other community groups, on-site RD
- Topics: Nutritional, physical activity, sleep, screen time, address stigma/bias, mental health, parenting skills
- The more hours, the better the outcome
- "Deliver the best available intensive treatment to all children with overweight and obesity"

Weight Loss Medications



- Always in conjunction with intensive lifestyle interventions
- Consider as young as 8y in severe cases, 12y for routine prescribing
- Choose medication based on mechanism of action and balancing side effect profile, especially against co-morbidities

 Insurance/cost
- Prescribe for 3 months then evaluate effect
- If < 3-5% weight loss achieved (*or a slowing of previous weight gain pattern, esp for younger children*), then increase dose or STOP and try another class
- Duration of use not brief. These are more likely to be <u>chronic</u>, like treating hypertension



Medication Options –

FDA approved

- GLP1s:
 - Semaglutide high dose: 12yo
 Liraglutide high dose: 12 yo
- Phentermine/Topiramate: 12yo
- Phentermine: > 16 yo for "short term"
- Metformin: 6yo
- Orlistat: 12 yo
- Buproprion/Naltrexone: 18yo
- Setmelanotide: 6y, MC4R abnl and BBS

Off Label

- Topiramate monotherapy
- Lisdexamfetamine approved for BED (18y) and ADHD (6y)

Partnering on Referrals



Sending Referrals:

- All growth curves please
- Labs (if you have them)
- Office note last check up
- Expectations with family:
 - Intensive program LOTS of help and support
 - $_{\odot}$ No meds on day 1
 - Full co-morbidity assessments and coordinated management

During and After Program

- Obesity is a chronic condition
- Expect relapses, set backs, and episodic changes
- Utilize multi-modal care on an ongoing basis
- Medications usually continue to be managed by tertiary care center – at least at this time....

Contact



jwilliams03@connecticutchildrens.org

Obesity Center at Connecticut Children's: 860-837-6717 <u>obesity@connecticutchildrens.org</u> <u>www.connecticutchildrens.org/obesity</u>




Injectables for weight loss

Fadi Al-Khayer, MD, FACE HHC Endocrinology

Is GIP as important as GLP 1?

GIP and GLP-1 Are Incretin Hormones Released From the Gut in Response to Food Intake^{1,2}




GIP is responsible for two-thirds of the incretin effect in healthy people, generating a more significant impact on insulin secretion than GLP-1¹


The incretin effect of GIP and GLP-1 is diminished in people with T2D³

Nauck MA, et al. Diabetes. 2019;68(5):897-900.
 Holst JJ. Metabolism. 2019;96:46-55.
 Nauck MA, et al. Diabetes Obes Metab. 2018;20(suppl 1):5-21.


Pharmacologic effects of GLP 1 and GIP analogues



Semaglutide (Wegovy, Ozempic) efficacy for weight loss in people with no type 2 diabetes (NEJM)




Tirzepatide (Mounjaro) efficacy for weight loss in people with no type 2 diabetes (NEJM)



Triple G (Retatrutide) efficacy for weight loss in people with no type 2 diabetes (NEJM) and ADA meeting June 2023

Changes in Body Weight



Weeks since Randomization

Placebo	Retatrutide						
	1 mg	4 mg (ID, 2 mg)	4 mg (ID, 4 mg)	8 mg (ID, 2 mg)	8 mg (ID, 4 mg)	12 mg (ID, 2 mg)	
	ID denotes initial dose.						

Adverse Events

Events	Assigned Maintenance						
	Placebo	1 mg	4 mg ID, 2 mg	4 mg ID, 4 mg	8 mg ID, 2 mg	8 mg ID, 4 mg	12 mg ID, 2 mg)
	(N=70)	(N=69)	(N=33)	(N=33)	(N=35)	(N=35)	(N=62)
Nausea	8 (11)	10 (14)	6 (18)	12 (36)	6 (17)	21 (60)	28 (45)
Diarrhea	8 (11)	6 (9)	4 (12)	4 (12)	7 (20)	7 (20)	9 (15)
Vomiting	1 (1)	2 (3)	4 (12)	4 (12)	2 (6)	9 (26)	12 (19)
Constipation	2 (3)	5(7)	5 (15)	2 (6)	4 (11)	4 (11)	10 (16)
Antidrug antibodies during treatment	1(1)	3(4)	4 (12)	5 (16)	5 (16)	2 (6)	11 (18)

Data are number of participants (percent). Data on antidrug antibodies were missing for 10 patients.

Oral GLP 1 analogues Rybelsus 25 and 50 mg for weight loss in people with no type 2 diabetes ADA meeting June 2023

Weight loss in OASIS 1 at 68 weeks for adults with obesity receiving oral semaglutide vs. placebo


Oral semaglutide 50 mg


15.1%

Placebo



Oral GLP 1 analogues orforglipron and weight loss in people with type 2 diabetes ADA meeting June 2023





Abbreviations: BMI = body mass index; LSM = least squares mean; OFG = orforglipron; SE = standard error.

CagriSema (coadministered semaglutide and cagrilintide an amylin analgoue) and weight loss in people with type 2 diabetes ADA meeting June 2023

 Patients receiving CagriSema lost a mean of 15.6% of body weight versus 5.1% with semaglutide and 8.1% with cagrilintide at week 32 (*P*<0.0001 for both)












Why do we think this is important?




What is the program all about?

- Curriculum-based education program for family physicians to run group visits based on healthy eating
- 3 group visits over 6 weeks
- Billed to insurance; billing and coding information included
- 3 Bonus sessions for the possibility of expansion

What are our goals?

- To provide the tools needed for family physicians to lead a nutrition education program in their offices
- To help patients learn more about small nutritional changes that can make a big difference in health
- To provide information that is sensitive to socioeconomic factors
- To create small communities of patients focused on healthy eating



Week 0 – 1st Group Visit Start from where you are.

Week 2 – 2nd Group Visit Food is Medicine.

Week 6 – 3rd Group Visit Food prep for long-term success.

Each visit will have a snack, an educational component, a recipe of the week and some homework.

What will we measure?

- Physician baseline self-assessment of nutrition knowledge
- Physician satisfaction with the program
- Patient baseline nutrition and knowledge, lipids, blood pressure, blood sugar, weight, BMI and waist circumference
- Follow up labs, measurements at 12 weeks
- Patient satisfaction with the program



Interested?

Contact: Kathy Mueller knmueller22@gmail.com

